Showing posts with label COPD guidelines 2016. Show all posts
Showing posts with label COPD guidelines 2016. Show all posts

Wednesday, November 23, 2016

Prevalence and burden of comorbidities in Chronic Obstructive Pulmonary Disease (FREE FULL TEXT ARTICLE from RESPIRATORY INVESTIGATION 2016)

We are happy to present you article Prevalence and burden of comorbidities in Chronic Obstructive Pulmonary Disease from RESPIRATORY INVESTIGATION 2016 which was published today!

http://www.sciencedirect.com/science/article/pii/S2212534516300703
The classical definition of Chronic Obstructive Pulmonary Disease (COPD) as a lung condition characterized by irreversible airway obstruction is outdated. The systemic involvement in patients with COPD, as well as the interactions between COPD and its comorbidities, justify the description of chronic systemic inflammatory syndrome. The pathogenesis of COPD is closely linked with aging, as well as with cardiovascular, endocrine, musculoskeletal, renal, and gastrointestinal pathologies, decreasing the quality of life of patients with COPD and, furthermore, complicating the management of the disease. The most frequently described comorbidities include skeletal muscle wasting, cachexia (loss of fat-free mass), lung cancer (small cell or non-small cell), pulmonary hypertension, ischemic heart disease, hyperlipidemia, congestive heart failure, normocytic anemia, diabetes, metabolic syndrome, osteoporosis, obstructive sleep apnea, depression, and arthritis. These complex interactions are based on chronic low-grade systemic inflammation, chronic hypoxia, and multiple common predisposing factors, and are currently under intense research. 
http://www.sciencedirect.com/science/article/pii/S2212534516300703
This review article is an overview of the comorbidities of COPD, as well as their interaction and influence on mutual disease progression, prognosis, and quality of life.
Free full text:

Friday, August 26, 2016

Therapeutic Monoclonal Antibodies for the Treatment of COPD (article from Drugs)

Dear friends we are happy to present you new article by world known experts in Respiratory Medicine Maria Gabriella Matera, Clive Page, Paola Rogliani, Luigino Calzetta, : Therapeutic Monoclonal Antibodies for the Treatment of COPD (article from last issue of Drugs journal)!
http://link.springer.com/article/10.1007/s40265-016-0625-9?wt_mc=socialmedia.f  acebook.1.SEM.ArticleAuthorAssignedToIssue
Chronic obstructive pulmonary disease (COPD) is a disorder characterized by a complex chronic inflammatory response that is largely poorly responsive to treatment with corticosteroids. Consequently, there is a huge need to find effective anti-inflammatory agents for the treatment of patients with this disease. Inhibition of cytokines and chemokines or their receptors using monoclonal antibodies (mAbs) could be a potential strategy to treat the inflammatory component of COPD. In this article, we review the therapeutic potential of some of these mAbs; however, to date there has been little or no therapeutic effect of any mAb directed against cytokines or chemokines in patients with COPD. This may reflect the complexity of COPD in which there is no dominant role for any single cytokine or chemokine. It is also likely that since the umbrella term COPD covers many endotypes having different underlying mechanisms, mAbs directed towards specific cytokines or chemokines should be tested in restricted and focused populations.
Full text:

Tuesday, August 9, 2016

Prevalence and burden of comorbidities in COPD (article from Respiratory Investigation, 2016)

Dear Respiratory friends we are happy to present you our new article on Prevalence and burden of comorbidities in COPD which appeared today in Respiratory Investigation.
Abstract
The classical definition of Chronic Obstructive Pulmonary Disease (COPD) as a lung condition characterized by irreversible airway obstruction is outdated. The systemic involvement in patients with COPD, as well as the interactions between COPD and its comorbidities, justify the description of chronic systemic inflammatory syndrome. The pathogenesis of COPD is closely linked with aging, as well as with cardiovascular, endocrine, musculoskeletal, renal, and gastrointestinal pathologies, decreasing the quality of life of patients with COPD and, furthermore, complicating the management of the disease. The most frequently described comorbidities include skeletal muscle wasting, cachexia (loss of fat-free mass), lung cancer (small cell or non-small cell), pulmonary hypertension, ischemic heart disease, hyperlipidemia, congestive heart failure, normocytic anemia, diabetes, metabolic syndrome, osteoporosis, obstructive sleep apnea, depression, and arthritis. 
https://www.researchgate.net/publication/305995597_Prevalence_and_burden_of_comorbidities_in_Chronic_Obstructive_Pulmonary_Disease
These complex interactions are based on chronic low-grade systemic inflammation, chronic hypoxia, and multiple common predisposing factors, and are currently under intense research. This review article is an overview of the comorbidities of COPD, as well as their interaction and influence on mutual disease progression, prognosis, and quality of life.
Full text:
on Researchgate:

Sunday, July 31, 2016

New Respiratory App - #GOLDCOPD app

In partnership with the Global Initiative for Chronic Obstructive Lung Disease - GOLD, Doctot has produced the official ‪#‎GOLDCOPD‬ App.
https://www.facebook.com/worldcopdday/videos/930941440348576/
This much-celebrated App uniquely provides the GOLD strategy for treating Chronic Obstructive Pulmonary Disease (COPD) in a user-friendly and easily navigable format with interactive tables and charts. Doctot #GOLDCOPD (which can be downloaded at: 
https://itunes.apple.com/ie/app/gold-copd-strategy/id576193649?mt=8 also contains the GOLD sanctioned Combined Assessment of COPD scale.

Follow Global Initiative for Chronic Obstructive Lung Disease - GOLD on facebook:

Sunday, July 3, 2016

Pocket Guide to COPD Diagnosis, Management, and Prevention – 2016 (Link for free download)

Pocket Guide has been developed from the Global Strategy for the Diagnosis, Management, and Prevention of COPD (2016 Update). Technical discussions of COPD and COPD management, evidence levels, and specific citations from the scientific literature are included in that source document.
https://www.facebook.com/worldcopdday/photos/a.431789760263749.1073741826.116682571774471/914253928683994/?type=3&theater

Thursday, June 30, 2016

Do we really need asthma–chronic obstructive pulmonary disease overlap syndrome?

Dear Respiratory friends we are happy to present you exciting article from The Journal of Allergy and Clinical Immunology by our Italian friends Mario Cazzola and Paola Rogliani on Hot Topic: Do we really need asthma–chronic obstructive pulmonary disease overlap syndrome? 

The association of asthma and chronic obstructive pulmonary disease (COPD) in the same patient, which is designated as mixed asthma-COPD phenotype or overlap syndrome (ACOS), remains a controversial issue. This is primarily because many conflicting aspects in the definition of ACOS remain, and it is extremely difficult to summarize the distinctive features of this syndrome. Furthermore, we are realizing that asthma, COPD, and ACOS are not single diseases but rather syndromes consisting of several endotypes and phenotypes and, consequently, comprising a spectrum of diseases. The umbrella term ACOS blurs the lines between asthma and COPD and allows an approach that simplifies therapy. However, this approach contradicts the modern concept according to which we must move toward more targeted and personalized therapies to treat patients with these diseases.  

http://www.jacionline.org/article/S0091-6749(16)30368-2/fulltext
Therefore we argue that the term ACOS must be abandoned and ultimately replaced when new phenotypes and underlying endotypes are identified and a new taxonomy of airway diseases is generated.

Full text:

Wednesday, June 29, 2016

GOLD 2016 update on Asthma-COPD Overlap Syndrome (Link for free download)



Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalent chronic diseases in the general population. Both are characterized by similar mechanisms: airway inflammation, airway obstruction and airway hyperresponsiveness. However, the distinction between the two obstructive disease is not always clear. Multiple epidemiological studies demonstrate that in elderly people with obstructive airway disease, as many as half or more may have overlapping diagnoses of asthma and COPD. A COPD-Asthma overlap syndrome is defined as an airflow obstruction that is not completely reversible, accompanied by symptoms and signs of increased obstruction reversibility. For the clinical identification of  overlap syndrome COPD-Asthma Spanish guidelines proposed six diagnostic criteria The major criteria include very positive bronchodilator test (increase in FEV1 ≥15% and ≥400 ml),  eosinophilia in sputum and personal history of asthma. Minor criteria include high total IgE, personal history of atopy and positive bronchodilator test (increase in FEV1 ≥12% and ≥200 ml) on two or more occasions. The overlap syndrome COPD-Asthma is associated with enhanced response to inhaled corticosteroids due to the predominance of eosinophilic bronchial inflammation.
https://www.facebook.com/worldcopdday/photos/a.431789760263749.1073741826.116682571774471/911633245612729/?type=3&theater
 The furture clinical studies and multicenter clinical trials should lead to the investigation of disease mechanisms and simultaneous development of the novel treatment.

Saturday, June 11, 2016

Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis (2016 article from Expert Opinion on Drug Safety)

Introduction:
Roflumilast is the only phosphodiesterase 4 inhibitor approved for the treatment of COPD patients with chronic cough and sputum, and a history of exacerbations, but the compliance to treatment is reduced by poorly tolerated adverse events (AEs).
Areas covered:
The synthesis of clinical evidences indicates that roflumilast 500μg once-daily increased the risk of AEs, with no impact on the risk of serious AEs (SAEs), compared with placebo. Gastrointestinal AEs were common in patients treated with roflumilast, that may also induce headache, backpain and insomnia. Roflumilast protects against COPD related AEs. The frequency of very SAEs was rare but greater in patients treated with roflumilast than placebo, although factors other than the study drug were related with these SAEs.
http://www.tandfonline.com/doi/abs/10.1080/14740338.2016.1199683http://www.tandfonline.com/doi/abs/10.1080/14740338.2016.1199683
Expert opinion:
The safety profile of roflumilast administered in combination with further drugs for the treatment of COPD should be investigated through specifically designed RCTs, and the post-marketing surveillance might help to characterize the real risk of very SAEs. Roflumilast may provide more benefit than harm in patients at high risk of severe exacerbations, and the therapy discontinuation may be reduced by a correct education of patients on the generally transient and mild-to-moderate nature of gastrointestinal AEs induced by this drug.
Full text:

Saturday, June 4, 2016

GOLD COPD Continuum of Care: 16 November 2016

Global Strategy for the Diagnosis, Management and Prevention of COPD (GOLD) presents Conference GOLD COPD Continuum of Care on 16 November 2016!
https://www.facebook.com/events/242452176134529/

A one day comprehensive educational symposium on the Global Strategy for the Diagnosis, Management and Prevention of COPD. This educational program will feature GOLD strategy authors and contributors providing expert opinion into best practice COPD management. This program is open to all healthcare providers involved in the care and management of patients with COPD, and is being held in conjunction with World COPD Day activities.
Faculty Speakers
Please check back later as we will be updating this information.
Dr. Gerard Criner, Philadelphia, PA
Dr. Roberto Rodriguez-Roisin, Barcelona, Spain
Dr. Jadwiga Wedzicha, London, United Kingdom
Dr. Claus Vogelmeier, Marburg, Germany
Dr. Nicolas Roche, Paris, France
Dr. David Halpin, Devon, United Kingdom
Please register early; on-site registration is $25.00 higher than pre-registration cost

Visit official GOLD Global Strategy for the Diagnosis, Management and Prevention of COPD (GOLD) facebook page: